London: The Oxford-AstraZeneca vaccine, whose Indian version is Covishield, is going through a rough phase. After 8 European nations temporarily suspended the vaccine due to possible blood clots, countries like Thailand are delaying its rollout.
The European Union’s drug regulator has now recommended adding severe allergy (anaphylaxis and hypersensitivity) as possible side effects.
This is based on 41 reports of possible anaphylaxis from around 5 million vaccinations in the UK.
It is important to note that the European Medicines Agency (EMA) is investigating the development of blood clots post vaccination, that prompted Italy, Norway and Denmark to suspend the jab. EMA, however, added that the vaccine is safe for use.
Anaphylaxis is known to be a common reaction to vaccines. The AstraZeneca shot carries a label that advises patients be kept under close observation for 15 minutes.
Also Read: Eight EU Nations Stop Using AstraZeneca Vaccine
Mumbai: The makers of the Sonu Sood starrer ‘Fateh’ released a thrilling, action-packed trailer of…
New Delhi: The Centre on Monday scrapped the 'no-detention policy' for Class 5 and 8…
Bhubaneswar: In a hit and run case, seven persons including a woman were critically injured…
Bhubaneswar: The Odisha government is committed towards achieving 7.5 GW of solar energy by 2030…
Mumbai: Dharma Productions new social media post has left netizens speculating about a sequel to…
Bhubaneswar: Asma al-Assad, wife of ousted Syrian president Bashar al-Assad, has reportedly filed for divorce…
This website uses cookies.